Greater emphasis on focus and efficiency for companies as market demands value in 2012.
Volatile Markets Take a Toll on Life-Sciences Initial Public Offerings
Strong pipelines, approvals, and deals drive up market cap.
Industry starts the year with a positive spin.
Business models that were used to create current value are no longer going to be effective going forward.
Biotech's mid-sized elites position themselves for growth.
After a bright start to the year, some of biotech's blue chip companies have seen their early gains turn into losses.
As the capital markets in the US and globally continue to strengthen, the biotech industry can expect to see a rise in initial public offerings this year.
The companies that have survived the financial meltdown are well placed to adapt to the new environment that we now are entering.
Biotech impressed investors with positive drug data, strong drug sales and earnings, and partnering deals.